p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance

Chen, Lindi; Tweddle, Deborah A.

doi:10.3389/fonc.2012.00173

Cited by 39 publications

(45 citation statements)

References 425 publications

(553 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding that p53-mutated nutlin-3-resistant neuroblastoma cells display a multidrug-resistance phenotype is in accordance with previous reports, suggesting p53 mutations to represent acquired resistance mechanisms in neuroblastoma [47]. Although p53 mutations appear to be generally rare in neuroblastoma increased rates of p53 mutations were detected at relapse [47].…”

Section: Resistance Acquisition To Mdm2 Inhibitors In Experimental Mosupporting

confidence: 91%

Resistance acquisition to MDM2 inhibitors

Činátl

Speidel

Hardcastle

et al. 2014

Biochemical Society Transactions

View full text Add to dashboard Cite

Various experimental strategies aim to (re)activate p53 signalling in cancer cells. The most advanced clinically are small-molecule inhibitors of the autoregulatory interaction between p53 and MDM2 (murine double minute 2). Different MDM2 inhibitors are currently under investigation in clinical trials. As for other targeted anti-cancer therapy approaches, relatively rapid resistance acquisition may limit the clinical efficacy of MDM2 inhibitors. In particular, MDM2 inhibitors were shown to induce p53 mutations in experimental systems. In the present article, we summarize what is known about MDM2 inhibitors as anti-cancer drugs with a focus on the acquisition of resistance to these compounds.

show abstract

Section: Resistance Acquisition To Mdm2 Inhibitors In Experimental Mosupporting

confidence: 91%

Resistance acquisition to MDM2 inhibitors

Činátl

Speidel

Hardcastle

et al. 2014

Biochemical Society Transactions

View full text Add to dashboard Cite

show abstract

“…Notably, p53 wild-type neuroblastomas make up the vast majority of neuroblastoma cases, as neuroblastomas only rarely harbor p53 mutations. 37, 38 …”

Section: Discussionmentioning

confidence: 99%

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance

Voges¹,

Michaelis²,

Rothweiler³

et al. 2016

Cell Death Dis

View full text Add to dashboard Cite

Resistance formation after initial therapy response (acquired resistance) is common in high-risk neuroblastoma patients. YM155 is a drug candidate that was introduced as a survivin suppressant. This mechanism was later challenged, and DNA damage induction and Mcl-1 depletion were suggested instead. Here we investigated the efficacy and mechanism of action of YM155 in neuroblastoma cells with acquired drug resistance. The efficacy of YM155 was determined in neuroblastoma cell lines and their sublines with acquired resistance to clinically relevant drugs. Survivin levels, Mcl-1 levels, and DNA damage formation were determined in response to YM155. RNAi-mediated depletion of survivin, Mcl-1, and p53 was performed to investigate their roles during YM155 treatment. Clinical YM155 concentrations affected the viability of drug-resistant neuroblastoma cells through survivin depletion and p53 activation. MDM2 inhibitor-induced p53 activation further enhanced YM155 activity. Loss of p53 function generally affected anti-neuroblastoma approaches targeting survivin. Upregulation of ABCB1 (causes YM155 efflux) and downregulation of SLC35F2 (causes YM155 uptake) mediated YM155-specific resistance. YM155-adapted cells displayed increased ABCB1 levels, decreased SLC35F2 levels, and a p53 mutation. YM155-adapted neuroblastoma cells were also characterized by decreased sensitivity to RNAi-mediated survivin depletion, further confirming survivin as a critical YM155 target in neuroblastoma. In conclusion, YM155 targets survivin in neuroblastoma. Furthermore, survivin is a promising therapeutic target for p53 wild-type neuroblastomas after resistance acquisition (neuroblastomas are rarely p53-mutated), potentially in combination with p53 activators. In addition, we show that the adaptation of cancer cells to molecular-targeted anticancer drugs is an effective strategy to elucidate a drug's mechanism of action.

show abstract

“…Additionally, different signalling pathways are involved in the tumour development. An overview is given in Figure 1 [14][15][16][17][18][19][20][21].…”

Section: Driver Mutations and Signalling Pathwaysmentioning

confidence: 99%

Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature

Benzel

Fendrich

2018

Digestion

View full text Add to dashboard Cite

Background: Pancreatic ductal adenocarcinoma is one of the most lethal types of cancer with a 5-year survival rate of around 7%. Due to the relatively poor prognosis, the potential need of an effective chemoprevention is highly needed. Summary: Different risk factors like smoking or hereditary tumour syndromes should be known for early detection of pancreatic intraepithelial neoplasia. Chemopreventive dietary agents include curcumin, capsaicin and flavonoid, whereas potential chemopreventive drugs compromise aspirin, metformin or statins. This review aims to give an overview on potential risk factors for the development of pancreatic cancer. Furthermore, we try to summarise known chemopreventive agents to support the fight against this lethal disease. Key Messages: On the one hand, there are natural agents that exhibit preventive properties and can lead to the prohibition of pancreatic cancer. On the other hand, there are drugs and agents that are currently used in other contexts and are thus already approved and studied in terms of their mechanisms of effects and the related secondary effects.

show abstract

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance

Cited by 39 publications

References 425 publications

Resistance acquisition to MDM2 inhibitors

Resistance acquisition to MDM2 inhibitors

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance

Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature

Contact Info

Product

Resources

About